Our Solutions   Erlotero 150 mg Tablets

Erlotero 150 mg Tablets

Erlotero 150Mg Tablet

*To be consumed as directed by physician.

Therapies:

Anti Neoplastics

Composition:

Erlotinib Hydrochloride IP equivalent to Erlotinib 150 mg

About Erlotero 150Mg Tablet

Erlotero 150 mg Tablets contains Erlotinib 150 mg, a targeted anticancer medicine belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor class. It is prescribed for the treatment of EGFR-positive non-small cell lung cancer (NSCLC) and, in combination with other medicines, pancreatic cancer, as recommended by an oncologist. Erlotinib works by blocking EGFR signaling pathways that promote the growth and spread of cancer cells, thereby slowing disease progression. Erlotero 150 mg should be used only under the supervision of a qualified oncology specialist.

Erlotero 150Mg Tablet

*To be consumed as directed by physician.


Usage Instructions

  • Take Erlotero 150 mg Tablets exactly as prescribed by your doctor.
  • It should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal, preferably at the same time every day.
  • Continue taking the medicine for the duration recommended by your oncologist.
  • Do not alter the dose or discontinue treatment without consulting your doctor.
  • Regular monitoring of liver function and overall health may be required during therapy.

    • Benefits and Use

  • Erlotero 150 mg Tablets is indicated for the treatment of EGFR-positive locally advanced or metastatic non-small cell lung cancer and, in selected cases, pancreatic cancer in combination with other anticancer medicines.
  • Erlotinib specifically targets EGFR-mediated signaling involved in cancer cell growth and multiplication, helping slow tumour progression and improve disease control.
  • When used under specialist supervision, it forms an important part of targeted cancer therapy and contributes to improved treatment outcomes in eligible patients.

    • Safety Information

  • Pregnancy:
  • Erlotero 150 mg should not be used during pregnancy unless the benefits clearly outweigh the risks. Effective contraception should be used by both men and women during treatment and for at least one month after the final dose.
  • Breastfeeding:
  • Breastfeeding is not recommended during treatment and for the period advised by your doctor after discontinuation.
  • Alcohol:
  • Consult your doctor before consuming alcohol during therapy.
  • Smoking:
  • Avoid smoking, as it can reduce Erlotinib blood levels and decrease treatment effectiveness.
  • Kidney Disorders:
  • Use with caution in patients with kidney impairment and under specialist supervision.
  • Liver Disorders:
  • Patients with liver disease should be monitored closely, and dose adjustments may be necessary.
  • Sun Exposure:
  • Erlotinib may increase sensitivity to sunlight; wear protective clothing and use sunscreen when outdoors.
  • Driving:
  • If you experience dizziness, fatigue, or vision disturbances, avoid driving or operating machinery.
  • Inform your doctor immediately if you develop severe diarrhea, persistent cough, breathing difficulties, mouth ulcers, or changes in vision.
  • Inform your healthcare provider about all medicines you are taking, particularly acid-reducing medicines, as they may interact with Erlotinib.

    • Ingredients

    Erlotinib Hydrochloride IP equivalent to Erlotinib 150 mg

    How to Use

  • Swallow one Erlotero 150 mg Tablets whole with water on an empty stomach.
  • Do not crush, chew, or break the tablet.
  • Avoid taking antacids, H2 blockers (such as ranitidine), proton pump inhibitors, or other acid-reducing medicines close to the dose unless advised by your doctor, as they may reduce the absorption and effectiveness of Erlotinib.
  • Drink adequate fluids during treatment and follow your healthcare provider's instructions.

    • Storage Information

    Store below 30°C in a cool, dry place, protected from moisture, heat, and direct sunlight.